China Manufacturing PMI Contracts Again as Recovery Remains Fragile 
Asian Tech Stocks Slide as Fed Rate Hike Bets Rise 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Dollar Holds Near Two-Week High as Fed Rate Hike Bets Rise 
Oil Prices Jump as U.S.-Iran Tensions Threaten Hormuz Supply 
Canada Backs €100B Global Defence Bank as G7 Support Lags 
Bessent Urges G20 to Rethink China Trade Ties 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
Ukraine Seeks Early EU Funds to Cover $27B Defence Gap 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Gold Prices Steady as U.S.-Iran Tensions Lift Inflation Risks 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Brazil, US Resume Tariff Talks as Trade Tensions Persist 
Add as a preferred source on Google
Celltrion revealed the results of its phase 3 clinical trial for its COVID-19 treatment drug called Regkirona. The final testing was said to have yielded good results, and the biopharmaceutical company headquartered in Incheon, South Korea, presented it at a conference in Europe.
The effectiveness of Celltrion’s Regkirona
As per The Korea Herald, Celltrion said on Tuesday, July 13, that its anti-body COVID-19 treatment can reduce the risk of the infection from becoming a severe case by 70%. Based on the final round of tests, the high-risk groups showed a reduced progression rate to severe infection by 72%.
The patients who were administered the Regkirona treatment were able to recover from COVID-19 in just 8.4 days. This was said to be 4.9 days faster compared to patients who used placebo treatment and recovered for 13.3 days.
For high-risk groups, Celltrion’s anti-body treatment helped patients recover for 9.3 days which is likewise faster by 4.7 days compared to the placebo group who recovered in 14 days. Moreover, the Korean biopharmaceutical company further discovered that its treatment significantly reduced viral titers in patients after they were given Regkirona.
Most importantly, there were no severe adverse effects or allergic reactions detected. Besides the mild and temporary reactions from patients, there have been no reports of severe responses to the drug. While the results of the trial were good, Celltrion is still testing if the treatment is also effective against other variants of COVID-19, such as the delta.
The presentation in Europe
The results of Celltrion’s antibody COVID-19 treatment were presented in Europe by Oana Sandulescu, who is an associate professor at Carol Davila University of Medicine and Pharmacy. She shared the results during the 31st European Congress of Clinical Microbiology and Infectious Diseases that was held online from July 9 to 12, according to The Korea Economic Daily.
Sandulescu attested that Regkirona significantly lowered the rate of progression for severe coronavirus infection symptoms and hastened the recovery time too. In any case, the associate professor took part in the clinical trial of Regkirona that was conducted from January to April with 1,315 participants from 13 countries.
